| Primary |
| Chronic Myeloid Leukaemia |
28.2% |
| Acute Lymphocytic Leukaemia |
13.9% |
| Prostate Cancer |
9.9% |
| Leukaemia |
6.5% |
| Non-small Cell Lung Cancer |
6.1% |
| Pain |
4.2% |
| Colorectal Cancer Metastatic |
4.0% |
| Nausea |
3.6% |
| Breast Cancer |
3.3% |
| Hypertension |
2.8% |
| Acute Myeloid Leukaemia |
2.6% |
| Vomiting |
2.5% |
| Sarcoma |
2.4% |
| Supplementation Therapy |
1.9% |
| Premedication |
1.8% |
| Constipation |
1.7% |
| Depression |
1.3% |
| Breast Cancer Metastatic |
1.2% |
| Pleural Effusion |
1.1% |
| Anxiety |
1.0% |
|
| Pleural Effusion |
22.1% |
| Vomiting |
9.4% |
| Pyrexia |
7.9% |
| Sepsis |
5.8% |
| Malignant Neoplasm Progression |
5.5% |
| Thrombocytopenia |
5.5% |
| Respiratory Failure |
5.3% |
| Pneumonia |
4.3% |
| Pulmonary Embolism |
4.1% |
| Rash |
3.4% |
| Hypoxia |
3.1% |
| Renal Failure Acute |
2.9% |
| Septic Shock |
2.9% |
| Subdural Haematoma |
2.9% |
| Sudden Death |
2.9% |
| Diarrhoea |
2.6% |
| Dyspnoea |
2.6% |
| Dehydration |
2.4% |
| Nausea |
2.4% |
| Hyperkalaemia |
2.2% |
|
| Secondary |
| Product Used For Unknown Indication |
31.0% |
| Acute Lymphocytic Leukaemia |
19.3% |
| Chronic Myeloid Leukaemia |
10.4% |
| Non-small Cell Lung Cancer |
4.1% |
| Prostate Cancer |
3.4% |
| Pain |
3.4% |
| Nausea |
3.3% |
| Drug Use For Unknown Indication |
3.0% |
| Vomiting |
2.8% |
| Constipation |
2.6% |
| Non-small Cell Lung Cancer Metastatic |
2.4% |
| Vitamin Supplementation |
2.1% |
| Cough |
2.1% |
| Acute Myeloid Leukaemia |
2.0% |
| Hypertension |
1.6% |
| Prophylaxis |
1.6% |
| Lymphocytic Leukaemia |
1.3% |
| Blood Cholesterol |
1.3% |
| Anxiety |
1.1% |
| Sleep Disorder |
1.1% |
|
| Thrombocytopenia |
12.4% |
| Vomiting |
11.8% |
| Pleural Effusion |
8.0% |
| Urinary Tract Infection |
7.4% |
| Dyspnoea |
6.9% |
| Renal Failure Acute |
6.0% |
| Sepsis |
6.0% |
| Pneumonia |
5.8% |
| Febrile Neutropenia |
5.5% |
| Pyrexia |
4.1% |
| Rash |
3.0% |
| Neutropenia |
2.7% |
| Tumour Lysis Syndrome |
2.7% |
| Urinary Tract Infection Staphylococcal |
2.7% |
| White Blood Cell Count Decreased |
2.7% |
| Acute Respiratory Failure |
2.5% |
| Haematemesis |
2.5% |
| Subdural Haematoma |
2.5% |
| White Blood Cell Count Increased |
2.5% |
| Malignant Neoplasm Progression |
2.2% |
|
| Concomitant |
| Chronic Myeloid Leukaemia |
31.3% |
| Acute Lymphocytic Leukaemia |
8.3% |
| Pain |
6.7% |
| Prophylaxis |
6.7% |
| Product Used For Unknown Indication |
5.6% |
| Prophylaxis Against Graft Versus Host Disease |
4.4% |
| Stem Cell Transplant |
4.4% |
| Haemochromatosis |
3.6% |
| Myelodysplastic Syndrome |
3.6% |
| Sleep Disorder |
3.6% |
| Renal Cell Carcinoma |
3.2% |
| Chemotherapy |
2.8% |
| Blast Crisis In Myelogenous Leukaemia |
2.4% |
| Depression |
2.4% |
| Graft Versus Host Disease |
2.4% |
| Chronic Myeloid Leukaemia Transformation |
2.0% |
| Thrombocytopenia |
2.0% |
| Bone Marrow Conditioning Regimen |
1.6% |
| Chronic Graft Versus Host Disease |
1.6% |
| Glioma |
1.6% |
|
| Drug Ineffective |
11.5% |
| Thrombocytopenia |
10.3% |
| Drug Resistance |
7.7% |
| White Blood Cell Count Decreased |
7.7% |
| Vomiting |
6.4% |
| Pyrexia |
5.1% |
| Rash |
5.1% |
| Stem Cell Transplant |
5.1% |
| Swelling |
5.1% |
| Urticaria |
5.1% |
| Liver Disorder |
3.8% |
| Nausea |
3.8% |
| Red Cell Distribution Width Increased |
3.8% |
| Tachycardia |
3.8% |
| Death |
2.6% |
| Drug Dispensing Error |
2.6% |
| Lung Infiltration |
2.6% |
| Malignant Neoplasm Progression |
2.6% |
| Muscular Weakness |
2.6% |
| Pain |
2.6% |
|
| Interacting |
| Antacid Therapy |
25.0% |
| Gastric Ph Increased |
25.0% |
| Leukaemia |
25.0% |
| Product Used For Unknown Indication |
25.0% |
|
| Headache |
50.0% |
| Pyrexia |
50.0% |
|
